Ranibizumab▼ | Teva UK
Teva Worldwide Product List
For members of the public:

Ranibizumab▼

Overview

▼ Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. The Patient Information Leaflet for products containing Ranibizumab from Teva can be downloaded below, along with other information such as Frequently Asked Questions where applicable. To contact Teva's Medical Information Service email: medinfo@tevauk.com or telephone: 0207 540 7117.

Available as
  • Solution for Injection

Date of preparation: April 2023
D: COB-GB-NP-00112 (V1.0) / T: COB-GB-NP-00102 (V1.0) / M: COB-GB-NP-00103 (V1.0)

Date of preparation: April 2023
D: COB-GB-00016 (V1.0) / T: COB-GB-00014 (V1.0) / M: COB-GB-00015 (V1.0)

Date of preparation: April 2023
D: COB-GB-NP-00104 (V1.0) / T: COB-GB-NP-00105 (V1.0) / M: COB-GB-NP-00106 (V1.0)

Teva UK Limited

Teva's Product List

Please confirm if you are a member of the public, or a patient prescribed a Teva medicine by a UK healthcare professional (or their caregiver) or if you are UK healthcare professional.

Patients: The information on the patients website is suitable for and solely intended for UK patients prescribed a Teva medicine following consultation with a UK healthcare professional (or their caregiver). By selecting this button you are confirming that you are a patient who has been prescribed a Teva medicine by a UK healthcare professional (or their caregiver).

Healthcare professionals: The information on the UK healthcare professionals website is suitable for and solely intended for UK healthcare professionals. By selecting this button you are confirming that you are a UK healthcare professional.


Date of preparation: April 2023
D: COB-GB-NP-00109 (V1.0) / T: COB-GB-NP-00110 (V1.0) / M: COB-GB-NP-00111 (V1.0)